Misregulated β-catenin responsive transcription (CRT) has been implicated in the genesis of various malignancies, including colorectal carcinomas, and it is a key therapeutic target in combating various cancers. Despite significant effort, successful clinical implementation of CRT inhibitory therapeutics remains a challenging goal. This is, in part, because of the challenge of identifying inhibitory compounds that specifically modulate the nuclear transcriptional activity of β-catenin while not affecting its cytoskeletal function in stabilizing adherens junctions at the cell membrane. Here, we report an RNAi-based modifier screening strategy for the identification of CRT inhibitors. Our data provide support for the specificity of these inhibitory compounds in antagonizing the transcriptional function of nuclear β-catenin. We show that these inhibitors efficiently block Wnt/β-catenin-induced target genes and phenotypes in various mammalian and cancer cell lines. Importantly, these Wnt inhibitors are specifically cytotoxic to human colon tumor biopsy cultures as well as colon cancer cell lines that exhibit deregulated Wnt signaling.
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high-throughput screen | oxazole | thiazole | thiazolidinedione | beta-catenin W nt genes encode secreted glycoproteins that belong to a family of conserved signaling molecules which regulate a plethora of fundamental developmental and cell biological processes (1) (2) (3) . Aberrant or sustained Wnt signaling has been linked to human disease, including cancers of the liver, colon, breast, and skin (2, (4) (5) (6) . The key mediator of canonical Wnt signaling is the transcriptional coactivator β-catenin (β-cat). The cytosolic level of β-cat is tightly controlled by a multiprotein destruction complex composed of Adenomatous polyposis coli (APC), Axin, and Glycogen synthase kinase-3β (GSK-3β), which phosphorylates β-cat and thereby, induces its ubiquitination and subsequent proteasomemediated degradation (Fig. 1A) (7) (8) (9) (10) . Stimulation of the pathway by Wnts results in inhibition of the destruction complex, leading to stabilization/activation of cytosolic β-cat, which translocates to the nucleus and activates transcription together with the Lymphoid enhancer factor/T-cell factor (LEF/TCF) family of transcription factors (1, (11) (12) (13) . Thus, catenin responsive transcription (CRT), which corresponds to the activation program of transcriptional targets of β-cat, is a critical aspect of the responsiveness of a cell to a specific Wnt stimulus. Most, if not all, Wnt-associated carcinogenesis results from misregulated CRT, thus making the β-cat-TCF4 complex an ideal therapeutic target for drug design (14) (15) (16) (17) (18) (19) .
Significant effort and resources have been invested in the identification of small-molecule prototypes capable of regulating CRT (20) (21) (22) (23) (24) . Some of these compounds were identified in cellfree assays, thus risking limited use of the compounds in cellular environments (20) . Other compounds, such as ICG-001, which block CRT by interfering with the ability of β-cat to bind CREB protein (CBP), raise possible concerns regarding specificity, because CBP is known to interact with numerous other transcription factors, thereby influencing many signaling pathways (23) . More recent efforts to identify Wnt signaling modulators have resulted in candidate compounds that inhibit Wnt signaling by influencing the stability and expression levels of β-cat (21, 22, 24) . Although the use of such compounds in inhibiting the transcriptional activity of β-cat can be easily envisioned, there is a significant risk that they may also perturb the function of β-cat in cellcell adhesive junctions (25, 26) . Such down-regulation of β-catdependent adherens junctions is often associated with the initial stages of tumor metastasis. Moreover, treatment with compounds reducing β-cat expression might prove deleterious to the overall structural integrity and viability of cells, resulting in undesired systemic effects in vivo.
Compounds that inhibit aspects of Wnt signaling upstream of the axin/APC/GSK-3β complex, such as secretion or reception of Wnt ligands at the plasma membrane (21, 27) or transduction of the Wnt signal by Dishevelled (Dvl) (27, 28) , could also result in cross-regulatory effects on other signaling events activated by Wnts. These include the non-canonical pathways that lead to PKC and JNK activation, resulting in calcium release and cytoskeletal rearrangements (1) . Moreover, therapeutic applicability of such compounds is limited in cases where the Wnt pathway is deregulated by mutations in downstream components of the pathway, such as Axin, APC, or β-cat. Finally, several of the enzymatic components of the Wnt cascade that could potentially serve as attractive targets for small molecules, such as GSK-3β, caesin kinase 1 alpha (CK1α), and beta-transducin repeat containing protein (β-TrCP), also modulate other signaling pathways, thereby diminishing their suitability as Wnt-specific therapeutic targets (24, 29) .
We reasoned that, for the purpose of developing CRT-inhibitory drugs, it would be ideal to identify compounds that can uncouple the function of β-cat in the nucleus from that at the plasma membrane. Our goal was to identify small molecules that would target CRT without promoting indiscriminate degradation of β-cat or inhibiting its interaction with E-cadherin (E-cad) and other junction proteins (30) (31) (32) (33) . We devised a highly targeted suppressor screen that incorporates advantages of RNAi technology so as to specifically modulate the activity of the β-cat-TCF transcriptional complex downstream of the axin-mediated degradation complex. The initial assay used the Wnt responsive luciferase reporter-dTF12 in Drosophila clone 8 (Cl8) cells, as previously described (34) . Use of Drosophila cells for the primary screen provided a robust assay in the absence of genetic redundancies present in the mammalian system. Wnt/β-cat signaling was activated by introducing dsRNAs specific for axin (Fig. 1A) , and we then assessed the effect of individual compounds from a small-molecule library on the resulting induction of dTF12 reporter activity. This allowed us to selectively target the Wnt cascade downstream of the destruction complex and avoid compounds that might interfere with pathway components farther upstream (Fig. 1A) . We therefore anticipated that the candidate compounds identified using this approach would affect the activated or stable pool of β-cat and modulate its interaction with proteins that mediate the nuclear function of β-cat (35-37).
Such compounds would have the advantages of being able to block activated CRT resulting from oncogenic mutations in β-cat itself and nuclear β-cat activity in tumors in which components of the degradation complex are compromised by mutation.
Results
Primary Screen. As proof of concept, we first confirmed that the dTF12 luciferase reporter was strongly activated on dsRNAmediated knockdown of dAxin (Fig. S1A) . Importantly, coknockdown of β-cat (arm) or dTCF (pan) along with dAxin markedly reduced the reporter activity, consistent with an absolute requirement of β-cat and dTCF to activate target genes downstream of dAxin (Fig. S1A ). The primary screen was thus designed to identify candidate small molecules that would phenocopy the loss of function of downstream modulators, such as β-cat or dTCF, in the absence of dAxin. The Z factor for the (A) Primary screen. dsRNA-mediated knockdown of Axin results in cytoplasmic stabilization of β-cat, which, on translocation to the nucleus, results in activation of the β-cat responsive dTF12 reporter. (B) dTF12-luciferase activity in response to treatments with a small-molecule library, normalized to plate average, shows that, for all compounds screened, most had little or no effect on Wg signaling. Cut-off for cherry picking lead hits was set at ±0.3 on a logarithmic scale (red dashed line), reflecting either a twofold activation (red oval) or reduction (blue oval). The x axis represents the compounds screened, and the y axis represents the log transformation of the fold change of the dTF12 reporter for individual compounds over that of the plate average. assay was determined to be 0.77, thereby indicating a robust assay system for a high-throughput screen (HTS) (Fig. S1A and SI Materials and Methods have a detailed description of Z factor). We screened 14,977 compounds from small-molecule libraries in the Institute of Chemistry and Cellular Biology (ICCB)-Longwood collection (ICCB, Harvard Medical School, Boston) for their effect on modulation of dAxin-dsRNA-induced dTF12 reporter activity/CRT in Drosophila Cl8 cells ( Fig. 1 B and C) . The screen was performed in high-throughput format in 384-well microtiter plates. The libraries included known bioactive compounds [National Institute of Neurological Disorders and Stroke (NINDS) custom collection, Specplus, and BIOMOL1 (www. biomol.com, Catalogue #2840)], fungal extracts comprising of a mixture of natural compounds (ICCB), and 10,752 molecules from the ChemDiv3 synthetic library, which is a large collection of low molecular weight and structurally diverse families/classes of compounds.
The primary screen identified 34 molecules that had a statistically significant inhibitory effect on the activity of the dTF12-luciferase reporter gene (total hit rate ∼0.3%) (Fig. 1B, blue  oval) . We call these compounds inhibitors of CRT (iCRT). The addition of these compounds to the cells strongly repressed the dTF12 reporter activity by >70% (Fig. 1B and Fig. S1 ). The known chemical structures of these iCRTs suggested that the most potent (iCRT3) belongs to the oxazole class of small molecules (Fig. 1E) . Interestingly, we identified nine oxazoles as potent inhibitors of the dTF12 reporter activity (Fig. 1E′) , which may suggest a shared mechanism and/or putative target for this class of iCRTs. The other lead inhibitors belong to the closely related thiazole (iCRT5) or thiazolidinedione (iCRT14) classes (Fig. 1E) . Thiazolidinediones have recently been reported to down-regulate Wnt/β-cat signaling in breast and prostate cancer cells (38, 39) . Importantly, none of the iCRTs, including iCRT3, -5, and -14 ( Fig. S1A′) , influenced the transcriptional activity of FOP-Flash luciferase reporter, which harbors mutations in the DNA binding sites for TCF (β-cat response element), showing specificity of the response. We also isolated eight compounds that significantly and reproducibly activated Wnt pathway activity as measured by the dTF12-luciferase reporter (Fig. 1B, red  oval) . However, this study focuses on the candidate inhibitors (iCRTs) because of their potential relevance to cancer therapy.
Secondary Screens. Epistasis analysis in Drosophila cells. To define the site of action of candidate iCRTs within the Wnt signaling cascade, we designed a series of cell-based epistasis assays. Several proteins, including CK1α, Slimb/βTrcp, and SkpA, are known to regulate the Wnt signaling cascade parallel to or downstream of dAxin. Each of these negatively regulates CRT, either by phosphorylation of β-cat or mediating its subsequent degradation through the ubiquitin-proteosome pathway (7) (8) (9) (10) . To test the epistatic relationship between the candidate compounds and these known regulators of the pathway, we first activated the Wnt pathway in Cl8 cells using dsRNA targeted to the negative regulator Slimb/βTrCP, which functions downstream of the Axin/ APC/GSK-3β complex, and assayed the effect of the iCRTs on dTF12 reporter activity in these cells. We were able to obtain 23 of 31 candidate inhibitors from commercial sources for this secondary analysis; of these, 21 compounds inhibited dTF12 reporter activity downstream of Slimb/βTrCP (Fig. S1B) . To gain further evidence that the compounds exert their inhibitory effect in the nucleus, we also tested them in Cl8 cells transfected with a construct encoding a degradation-resistant form of β-cat, S37Aβ-cat ( Fig. 1C and Fig. S1B ) (40) . As shown in Fig. 1C , the representative candidate compounds iCRT3, -5, and -14 strongly inhibited S37Aβ-cat-induced dTF12 activity to a similar extent as observed in response to dAxin knockdown. The inhibitory effect of the compounds on the activity of S37Aβ-cat provided further evidence that they exert their effect on Wnt responsiveness at the level of CRT in the nucleus and that the inhibition is independent of levels or nuclear accumulation of β-cat. IC 50 of most of the candidate inhibitors for the luciferase reporter assay was found to lie in the nanomolar to micromolar range (Table S1) , consistent with high potency for inhibiting the Wnt signaling pathway. Pathway and species specificity of candidate iCRTs. We next tested whether the inhibitory action of the candidate compounds identified in the primary screen was specific to CRT by assaying their effects on other conserved cell signaling pathways. First, we asked if the iCRTs modulate β-cat-independent noncanonical Wnt signaling. For this, we assayed their effect on phosphorylation of Dvl induced by either Wnt3a or Wnt5a because, in each case, this is mediated independently of canonical Wnt signals (41) . As shown in Fig. 1D , we observed no effect of iCRTs on Wntmediated Dvl phosphorylation, with the exceptions that, at higher doses, iCRT3 led to partial inhibition of phosphorylation induced by Wnt5a and iCRT14 showed a modest reduction in the amount of Dvl but had no effect on Dvl phosphorylation itself. These data indicate that, at the lower doses, which are sufficient to antagonize canonical Wnt-mediated CRT, the inhibitors did not prevent noncanonical Wnt signaling through Dvl.
We next monitored the activity of Patched luciferase (Ptc-luc) and STAT-luciferase (STAT-luc) (29, 42) as readouts for the Hedgehog (hh) and Janus kinase/STAT signaling pathways, respectively, in Drosophila cells and CSL luciferase (CSL-luc) as a reporter for Notch signaling pathway in mammalian HEK293 cells ( Finally, some of the candidate iCRTs, such as iCRT4, -9, -16, and -21, robustly modulated the other signaling pathway reporters and therefore were discarded from further analysis here (Fig. S1C ). Taken together, these results indicated that at least some of the candidate inhibitors isolated in the Drosophila cell screen also robustly and specifically suppressed CRT in mammalian cells.
Modulation of β-Cat-TCF Complex by Candidate Inhibitors/iCRTs. Molecular regulation of β-cat-TCF protein complexes by candidate iCRTs.
To test whether the lead iCRTs compromised the integrity of β-cat-TCF4 complexes, we preincubated purified recombinant His-tagged β-cat with candidate inhibitors at different concentrations and assayed its ability to bind a purified GST-tagged TCF4 N-terminal domain. This domain of TCF4 has previously been shown to be sufficient for formation of β-cat-TCF4 complexes (43, 44) . iCRT3, -5, and -14 noticeably reduced the efficiency of inhibitor-treated β-cat to bind the N-terminal domain of TCF4 ( Fig. 2A) . We next performed coimmunoprecipitation (coIP) assays to examine whether the iCRTs could disrupt endogenous β-cat-TCF complexes in a cellular context. As shown in Fig. 2B , treatment of S37Aβ-cat-transfected HEK293 cells, with increasing concentrations of iCRT3, -5, and -14, significantly inhibited β-cat-TCF interactions. This suggests that all three lead compounds are CRT inhibitors that function by inhibiting direct interactions between β-cat and TCF4. When normalized for input and loading, at concentrations that are sufficient to inhibit β-cat-TCF4 interactions, the iCRTs had minimal or no effect on β-cat-E-cad ( Fig. 2 A and B) or β-cat-α-cat interactions (Fig. S2A) , suggesting that these compounds do not influence β-cat's interactions with other cognate protein partners indiscriminately. CoIP assays of nuclear extracts prepared from Drosophila Cl8 cells treated with Axin dsRNA also showed a significant reduction in the amount of TCF4 interacting with endogenous β-cat in the presence of the inhibitors (Fig. S2B) . Modulation of DNA binding of TCF by iCRTs. Next, we wanted to explore whether candidate iCRTs modulate the STF16 luciferase activity by impacting TCF binding to DNA. We used TCF fusion contructs, ΔβBD-TCF-VP16 and ΔNLEF-β-cat, that can robustly activate the Wnt reporter independent of TCF-β-cat interaction but are dependent on the inherent ability of TCFs to bind DNA. As shown in Fig. S2 C and D, whereas iCRT3 and -5 had no significant effect on the reporter activated by either ΔβBD-TCF-VP16 or ΔNLEF-β-cat, iCRT14 reduced the STF16 response by ∼50%. These results suggest that iCRT14 can also interfere with TCF binding to DNA in addition to its ability to influence TCF-β-cat interaction. In silico docking of iCRTs onto the co-crystal structure of β-cat/Tcf. To seek evidence of structural complementarities between the inhibitors and the β-cat protein surface, we performed in silico docking analysis based on the β-cat crystal structure. A similar computational approach was recently used by Shan et al. (28) , who used structure-based virtual ligand screening (VLS) of a smallmolecule library to identify a compound that can specifically bind the PDZ domain of Dvl protein (28) .
Distinct residues have been shown to be structurally, functionally, and energetically important for the interaction of β-cat with its different protein partners (44) (45) (46) . For example, Lys312 and Lys345 on β-cat form specific electrostatic contacts with Glu16 on TCF, whereas Lys435 pairs with Asp16 on TCF, and Phe253 and Phe293 together bury a specific hydrophobic surface with Leu48 on TCF (45) (46) (47) (48) (49) . Furthermore, mutations in Lys312 and Lys435 have been shown to attenuate the ability of β-cat to activate transcription of the luciferase reporter TOPFlash (50) . We anticipated that the lead iCRTs might bind to one or more of these areas and thereby be able to interfere with β-cat-TCF interactions specifically. In silico analyses of the co-crystal structure of β-cat-TCF4 revealed that there are ∼20 druggable pockets on the β-cat protein surface, including the specific surfaces for α-βcat interaction with TCF and E-cad (Fig. S2D ). An unbiased computational molecular docking screen of ∼1,000 randomly chosen compounds from the initial screening library revealed that iCRT5 and -3 dock preferentially into a TCF-specific pocket lined by Lys435 and Arg469, respectively, on β-cat. The docking is highly specific, with both a good energy score and significant energy gap apparent between the lowest energy docked conformation and other conformations from the same and other pockets (Materials and Methods and Fig. 2 C and D) . The docked conformation places a carboxyl (-COOH) group on iCRT5 into a position that mimics interactions mediated by the side chain of Asp16 on TCF4 with K435 on β-cat (Fig. 2E and Fig. S3E ). iCRT3, however, is placed in a position where its -NR group is competent to form a hydrogen bond with Arg469 on β-cat, a residue that is critical for stabilizing β-cat-TCF4 interactions (45) (Fig. 2F) . The structures of these two compounds are thus highly compatible in terms of molecular shape, electrostatics, and solvation energy, with a pocket on the β-cat protein surface that overlaps the TCF4 binding site. The docking results for iCRT3 and -5 therefore rule out a structural incompatibility between these compounds and the β-cat protein surface and predict their location of binding on the β-cat molecular surface. iCRT14 showed clear shape and energy complementarities with more than one β-cat surface pocket but resulted in a weaker prediction of the exact site of interaction. Thermal melt analysis. As a preliminary approach to investigating direct binding of iCRT3, -5, and -14 to the β-cat-TCF4 complex, we conducted thermal melt analysis (51) of purified β-cat-TCF4 complexes with and without iCRTs. This method analyzes temperaturedependent denaturation and is sensitive to the binding of small molecules or other protein ligands. As shown in Fig. 2 G-I, the addition of iCRT3, -5, and -14 causes a change in the melting temperature of β-cat-TCF4 complexes from the native value of 56.8°C by as much as 2°C (Fig. 2 G-I) . To confirm the validity of this method in studying protein-small molecule interactions, we performed similar thermal melt experiments with the FKBP12 and Rapamycin, which form a well-characterized protein-drug complex (52, 53) , and observed a temperature shift of ∼1.5°C in the presence of Rapamycin (Fig. S3E) . It is notable that the ability of the iCRTs to disrupt both endogenous and purified β-cat-TCF complexes (Fig. 2 A and B and Fig. S2B ) was comparable with the extent of reduction observed between bacterially purified GST-TCF4 and His-β-cat bearing a K435A substitution (Fig. S3 C and D) . These data collectively imply that interfering with a single site of interaction between two proteins, while not disassembling the complex entirely, is nevertheless sufficient to inhibit a cellular function such as transcription. The predictive value of in silico docking studies is corroborated by the cellular evidence that these compounds act at the level of β-cat or downstream. Taken together, our data from biochemical interaction studies, thermal melt analyses, and in silico analyses strongly support the hypothesis of direct binding of candidate iCRTs to β-cat and disruption of β-cat-TCF4 interaction as their mechanism of CRT modulation.
Inhibition of Wnt-Induced Phenotypes in Murine and Human Cancer
Cell Lines. For the candidate iCRTs to have therapeutic potential in activated CRT-related diseases, they should be capable of inhibiting a variety of Wnt/CRT-induced cellular phenotypes. We first evaluated their effects in a phenotypic assay using the Wnt responsive mouse mammary epithelial cell line C57MG (Fig. 3) . Expression of Wnt genes, such as Wnt1 or Wnt3a, in these cells results in cellular transformation manifested by a change from an epithelium-like morphology to spindle-shaped cells with chordlike actin bundles (54, 55) . Treatment with purified Wnt3a protein has a similar effect (56) . Addition of candidate iCRTs to such cells in the presence of Wnt3a resulted in significant inhibition of the transformation phenotype (Fig. 3 B-F) . We quantified these phenotypic changes using an automated imaging system and algorithm that measures the degree of anisotropy of actin fiber alignments within each cell. The anisotropy is the measure of the SD of the angles projected by each of the actin fibers relative to the normal; a low SD reflects an increase in Wnt-induced transformation as the fibers become more aligned. Thus, control nontransformed C57MG cells show a normal bell-shaped distribution of the degree of fiber alignment (Fig. 3B″) . Wnt3a treatment reduces the degree of anisotropy and results in a skewed distribution of fiber alignment (Fig. 3C″) . However, this shift is robustly inhibited by treatment with the three candidate iCRTs (Fig. 3 D″-F″) . In principle, this prevention of transformation could result from either inhibition of CRT or downstream antagonistic effects on the gene products that mediate the morphological change. To investigate this, we used quantitative RT-PCR (qPCR) to examine the mRNA levels of Wnt-1 induced secreted protein 1 (WISP1), a key β-cat target in C57MG cells that is implicated in transformation (57) . As shown in Fig. 3G , treatment of Wnt3a-induced cells with iCRTs resulted in a significant reduction in WISP1 mRNA levels. This further supports the conclusion that these compounds specifically interfere with β-cat's nuclear signaling activity (CRT), as intended by the design of the primary screen.
Next, we tested the efficacy of iCRTs on MCF7 human breast adenocarcinoma cell lines (a pathologically relevant model for Wnt-induced cell invasion). Activation of Wnt signaling in the otherwise noninvasive MCF-7 cell line leads to acquisition of invasive capacity (58) . Recent studies show that this results from β-cat-mediated transcriptional activation of AXN2, which ultimately results in the down-regulation of E-cad expression (58) and concomitant invasion. MCF-7 cells stably transduced with retroviruses expressing HA-tagged S37Aβ-cat were cultured in the presence of iCRT compounds or DMSO and assayed for induction of AXN2 transcription by qRT-PCR and invasiveness in matrigel-coated Boyden chambers. As shown in Fig. 3H , S37Aβ-cat-HA strongly induced expression of AXN2 compared with control cells transduced with vector alone. This activation was robustly inhibited by the candidate iCRTs in a dose-dependent manner (Fig. 3H) . Associated with the S37Aβ-cat-HA-mediated induction of AXN2 in MCF7 cells was a dramatic increase in their capacity to invade Matrigel in transwell assays (Fig. 3I) . This increased invasive behavior of MCF7-S37Aβ-cat-HA cells was significantly blocked in a dose-dependent fashion by the candidate iCRTs compared with DMSO control (Fig. 3I) .
Immunostaining for E-cad in MCF7-S37Aβ-cat-HA stable cells revealed a noticeable down-regulation of E-cad expression at the plasma membrane compared with control MCF7 cells (Fig. S4 F and G) . This was also observed in MCF7 cells transfected transiently with S37Aβ-cat and CMV-GFP ( Fig. S4 A and  B) . Treatment of the stable transfectants with iCRTs inhibited the loss of membranous E-cad as opposed to DMSO, which had no effect (Fig. S4 G-J) . The block in down-regulation of membranous E-cad in MCF7-S37Aβ-cat-HA cells correlates with the reduced migration of the iCRT-treated cells that we observed in the migration assay ( Fig. 3H and Fig. S4 ). Taken together, these data suggest that the candidate small-molecule inhibitors act at the level of CRT and thus, are capable of modulating CRTinduced molecular and morphological changes in a variety of Wnt responsive cells. (59) . Importantly, inhibition of Wnt/β-cat signaling in such cancer cells blocks the prosurvival pathway and induces apoptosis (60) . To test the inhibitory effect of candidate iCRTs on the transcription of endogenous Wnt/β-cat target genes in HCT116 cells, we performed qRT-PCR assays for CYCD1 and AXN2. These are well-characterized targets of CRT, and their expression was reduced in response to transfection with siRNA against β-cat (Fig.  4A) . We also observed a significant reduction in AXN2 and CYCD1 mRNA in HCT116 cells treated with iCRT3, -5, and -14 (Fig. 4B) . Importantly, the extent of inhibition by iCRTs was similar to that observed on siRNA-mediated knockdown of β-cat (Figs. 4 A and B) . Lysates prepared from iCRT-treated cells showed a corresponding reduction in CYCD1 protein levels compared with DMSO-treated controls (Fig. 4C) . Similar results were also obtained with C-MYC, another well-documented Wnt target (Fig. S3 A and B) .
We next analyzed the iCRT-treated HCT116 cells by flow cytometry and observed a marked cell cycle arrest in the G0/G1 phase, consistent with the reduction in CYCD1 expression (Fig.  4 D-G) . Effects of iCRTs were also tested on the colon cancer cell line HT29, which bears a mutation in the APC gene resulting in abnormally high levels of transcriptionally active β-cat (61). Compound-treated HT29 cells (Fig. 4 H-K) showed strong G0/ G1 arrest, as observed in HCT116. This cell cycle arrest in the presence of iCRTs correlated with a drastic reduction in both the number of cells staining positive for phospho-histone3 (Fig. 4 L-P and L′-O′) and the number of cells that incorporated BrdU (Fig. 4Q) . The iCRT effects on cell growth and proliferation observed in the HCT116 and HT29 cell lines were not seen in HEK293, C57MG, MCF7, or Drosophila Cl8 cells after overnight exposure to the compounds. Thus, of the cell lines tested, growth inhibition was only observed in those that exhibit constitutively elevated levels of CRT and are thought to be dependent on sustained Wnt/CRT activity for their survival. Our data suggest that this property may allow the compounds to be used for specific therapeutic purposes to induce apoptosis of Wnt-dependent can- and sutent (STN) . Two assay endpoints, the delayed loss of membrane integrity and the ATP content by luciferin-luciferase, were used to assess drug-induced cytotoxicity and determine the sample-specific IC 50 for each of the drugs, as previously described (62) . iCRT3 at concentration ranges of 6.25-100 μg/mL showed cytotoxicity in human primary culture specimens with an average IC 50 of 36 μg/mL. Strikingly, this is in a range comparable with that for the other drugs tested: 5FU = 77 μg/mL; CAMP = 53 μg/mL; IRESSA = 10.7 μg/mL; L-OHP = 6.7 μg/mL; MMC = 1.7 μg/mL; STN = 7.3 μg/mL. The response of different patient samples to the drugs tested, as judged by the SEM of individual IC 50 values, reveals differential sensitivity of each of the patient samples to iCRT3 as well as to the other drugs (Fig. 4R) . This underscores the fact that response to particular therapeutic agents depends on several factors such as progress of disease and genetic variation. Nonetheless, the observation that three patient samples were highly sensitive to iCRT3, with IC 50 values comparable with those of well-established drugs, is remarkable in that this compound was identified in a primary screen and has not undergone any chemical modifications. This, coupled with the fact that three patient samples were insensitive to iCRT3, suggests that the compound is not a general cytotoxin and thus offers significant potential for its further improvement as a pharmacological agent. HCT116 and HT29 xenografts. Due to limited commercial availability of the candidate iCRTs and their structural as well as functional similarities, we selected iCRT14 for in vivo testing. We chose the HCT116 and HT29 xenograft models: both of these result in rapidly proliferating tumors when implanted s.c. in athymic nude mice. After measurable tumors of at least 80-120 mm 3 volume were established, the animals were administered iCRT14 (dissolved in DMSO) at a concentration of 50 mg/kg. The compound was administered by i.p. injection three times a week for 3 wk. Immunostaining of xenograft sections after different time periods revealed a marked decrease in CycD1 compared with DMSOtreated controls (Fig. S5 A and B) . This coincided with reduced proliferation of the tumors, reflected by fewer numbers of cells staining positive for phospho-histone3 in drug-treated tumors (Fig. S5 C and D) ; similar results were seen in HT29 xenografts (Fig. S5 E-H) . Furthermore, these effects were correlated with a marked reduction (∼50%) in the initial growth rate of tumors within the first 3 wk (∼day 19) of compound administration (Fig.  S5 I and J) . After day 19, however, the rate of tumor growth was comparable with that of DMSO-treated control. Administration of a lower concentration of compound (20 mg/kg) by minipump also resulted in identical effects in HCT116 xenografts (Fig. S5I) . Importantly, throughout the course of the study, the mice did not display any signs of systemic toxicity or weight loss that would indicate off-target or nonspecific effects.
It is possible that the tumor growth results above could have been influenced by a slow rate of angiogenesis relative to the rapid growth rate of the tumor mass in such xenografts (63) . Thus, cells that are far removed from the growing vasculature might continue to proliferate at rates comparable with DMSO-treated controls. Also, the iCRT-treated tumors exhibited a marked increase in necrosis compared with DMSO controls, and the volume of necrotic tissue may contribute to the gross measurement of external tumor volume. It is, therefore, possible that the modest reduction in compound-treated xenograft volume is partially influenced by the reduced capacity for clearance of necrotic tissue in immunodeficient mice. Additionally, the compound may be metabolized rapidly in vivo, thus reducing its bioavailability. Nonetheless the consistent, albeit modest, reduction of tumor xenograft growth that we observed is particularly striking given that this is an unmodified compound from a primary screen.
Discussion
A key feature in early drug discovery is the design and implementation of an efficient and reliable screening strategy. We anticipate that the results from our study will encourage the incorporation of similar RNAi-based targeted screening methodologies for identification of specific small-molecule modulators of other cell signaling pathways in a physiological context.
Although protein-protein interaction surfaces have traditionally been challenging targets for drug development, there is increasing evidence from several recent studies that such interactions can indeed be targeted by small molecules that compete for hotspots of interactions on the surface of target proteins (64) . The data that we present here corroborate the previously postulated notion (20) that specific interference of the protein interaction surfaces between endogenous β-cat and TCF (and perhaps other components of the CRT complex) is not only feasible but also a viable strategy that can be used to modulate nuclear functions of β-cat in a cellular context. Importantly, the iCRTs identified in this study represent a significant increase in efficacy compared with a previously known inhibitor, such as Calphostin C (20) , that was shown to use a similar inhibitory mechanism on Wnt responsive reporter activity (Fig. S6) . Although our results show that the candidate iCRTs can directly influence the interaction between β-cat and its transcriptional partner TCF4, confirmation of these specific interactions and their structural details must wait for the solving of crystal structures of β-cat in complex with the candidate small molecules, which is currently underway. Nonetheless, the results from our molecular docking studies provide preliminary testable hypotheses in this regard. Future studies will also test the possibility of whether some of the candidate iCRTs influence pair-wise interactions between the other core components of the β-catenin transcriptional complex, such as Bcl9 and Pygo.
We envision that small molecules identified in screens such as those reported here can serve as prototypes for the development of antitumor drugs targeting CRT programs in different cancers. Although there is a clear need for improving the efficacy/potency of the lead compounds that we have identified in this initial study, we believe that our lead iCRTs (iCRT3, -5, and -14) satisfy a required profile for further investigation as inhibitors of tumor establishment and/or metastasis in vivo. Such a profile consists of five components: (i) an IC 50 in the nanomolar to micromolar range in assays of pathway activity using luciferase-based Wnt reporters; (ii) low complexity compounds with molecular weights in the range of <300-400 Da; (iii) the ability to inhibit direct interactions of β-cat with its cognate transcription factors, such as TCF4, without indiscriminately affecting its interaction with protein partners at the plasma membrane, such as E-cad and α-cat, and/or the ability to disrupt binding of TCF/LEF transcription factors onto their cognate DNA binding sites (iCRT14 in Fig. 2 C and D) ; (iv) the ability to inhibit transcription of known downstream target genes of β-cat, such as WISP-1, Axin-2, CycD1, and c-myc, in variety of cell types without affecting β-cat protein expression levels; (v) the ability to inhibit a variety of Wnt responsive phenotypes, such as cellular transformation in C57MG cells, cell invasion in MCF7 cells, and cell growth and proliferation in Wnt/β-cat-addicted cancer cells, such as HCT116 and HT29; and (vi) the modest but consistent potency in inhibiting CRT in an in vivo xenograft context while not causing any significant systemic toxicity. Most importantly, our studies of the cytotoxic effects of iCRTs in human colon cancer samples indicate an efficacy comparable with that of FDAapproved cancer drugs such as 5 FU. These iCRTs are therefore attractive lead compounds that can now be further developed for therapeutic intervention in Wnt-associated cancers.
In conclusion, our targeted screening methodology resulted in the identification of small molecules that can modify Wnt signaling activity at a specific step in the signal transduction cascade. Similar RNAi-based integrated screening technology should be widely applicable to a variety of other signaling pathways implicated in human development and disease.
Materials and Methods
Primary Screen. The primary screen was conducted in a 384-well format, for which 40 × 10 3 Drosophila Cl8 cells were transfected with 50 ng each dTF12-LF Wg signaling reporter and PolIII-RL normalization reporter as well as 100 ng dAxin dsRNA using Effectene transfection reagent (Qiagen). After 4 d of incubation to ensure complete knockdown of Axin, small-molecule compounds from the indicated libraries were added to a final concentration of 9 ng/μL in a final volume of 60 μL. After incubation for ∼16 h, normalized luciferase activity was measured using the Dual-Glo luciferase system (Promega). The Z factor, which reflects the fidelity and efficacy of the screening paradigm, was calculated as follows: Z factor = 1 − [3(σp − σn)/|μp − μn|], where σp = SD of positive control, σn = SD of negative control, μp = mean of positive control, and μn = mean of negative control.
Constructs. SuperTopFlash (STF16; 16×) and 12XdTOP (dTF12) constructs have been previously described in DasGupta et al. (34) . HA-tagged S37Aβ-cat was prepared by amplifying S37Aβ-cat with specific primer pairs, wherein the HA tag sequence was incorporated into the reverse primer. S37Aβ-cat-HA was cloned into the BamH1/Sal1 sites in pBabe for generation of retroviral transduction construct.
Cell Lines. HCT116 and HEK293T/17 cell lines were obtained from ATCC. The MCF-7 cell line was a gift from Michael Garabedian's laboratory (New York University School of Medicine, New York, NY). The C57MG cell line was a gift from Pamela Cowin's laboratory (New York University School of Medicine, New York, NY). HCT116 cells were cultured in McCoy's 5A medium supplemented with 10% FBS. MCF7, C57MG, Rat2, and HEK 293/T17 cells were cultured in DMEM supplemented with 10% FBS. Drosophila Cl8 cells were obtained from Drosophila RNAi Screening Center (DRSC), Harvard University, Cambridge, MA, and cultured in Shields and Sang M3 Insect Media supplemented with 0.0125 IU/mL insulin (16634; Sigma-Aldrich), 2.5% fly extract, and 2% FBS at 23°C. Detailed protocols for the cell-based assays are described in SI Materials and Methods.
CoIP and Target Accumulation Assays. Standard techniques were used for coIP assays between β-cat and TCF-4 in HEK293T/17 cells. Detailed protocol described in SI Materials and Methods.
qRT-PCR Analysis. Target accumulation validations were performed by qPCR after treatment with the lead compounds. Briefly, cells were treated with specified concentrations of compounds for 1 d (MCF7 cells and HCT116 cells) or 5 d (C57MG cells) and lysed in 50 μL cell lysis buffer (AM8723; Ambion) at 75°C for 10 min. First-strand cDNA was prepared using a High-Capacity Reverse Transcription Kit (Applied Biosystems) as per the manufacturer's instructions. Real-time qPCR was carried out for Axn2, E-cad, CycD1, c-Myc, and GAPDH2 (endogenous control) using prevalidated gene-specific primer pairs from Qiagen and the SYBR green PCR master mix from Applied Biosystems. Data analysis was performed using the MxPro-Mx3005P system from Stratagene using the ddCt method.
Thermal Stability Analysis. Purified β-cat-His and TCF4-N-GST were mixed in a 1:2 molar ratio in 1× PBS at room temperature in the presence of various concentrations of iCRTs and 0.5× SYPRO Orange (S6651; Invitrogen). Samples were heated in 96-well plates using a LightCycler 480 System (Roche) from 20°C to 95°C at a ramp rate of 0.06°C per s. Fluorescence readings were acquired at 0.1-s intervals during the heating phase. Melting temperatures were calculated by plotting negative derivates of fluorescence intensity reading against temperature. Inflection point on the negative derivative curve is considered the melting temperature (Tm).
